From paper to the cloud

The author describes the benefits of a cloud platform also with regard to the exchange between different research and development teams.
The focus of the development of an approved gene therapy is on adeno-associated virus (AAV)-based gene therapies for the treatment of patients affected by hemophilia, Huntington's disease and other severe genetic disorders. This involves the use of a modular and validated cloud platform. But before moving to a cloud-based platform, paper-based workflows make it difficult to track test results and collaborate across teams and sites. That's how many life sciences companies feel, as digitization is not advancing very quickly, especially in research and development (R&D) departments. Read here the article.